ARTV
Artiva Biotherapeutics, Inc.·Healthcare
6.81
0.147%(+0.01)
Market ClosedLast Updated: — ET
52W L: $1.4752W H: $7.75
ARTV NEWS
globenewswire.com
3d ago
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a panel as well as a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 2:15 p.m. EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website.
defenseworld.net
Mar 15
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decrease in Short Interest
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV - Get Free Report) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 148,835 shares, a decrease of 21.3% from the February 12th total of 189,121 shares. Based on an average daily volume of 129,793 shares, the days-to-cover ratio
globenewswire.com
Mar 10
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026
globenewswire.com
Feb 25
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.
globenewswire.com
Feb 24
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.
globenewswire.com
Feb 19
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors
SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis.
